Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody[1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively[2].
Product Specifications
CAS Number
1428935-60-7
Product Name Alternative
MEDI 4736
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/durvalumab.html
Purity
99.60
Solubility
H2O
Smiles
[Durvalumab]
Molecular Weight
(146.32 kDa)
References & Citations
[1]Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.|[2]Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3 (9) :1052-62.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
